Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


2009 Part D plan instructions

Executive Summary

Final version of CMS "call letter" to potential Part D sponsors outlining requirements for the 2009 benefit year reiterates most of the drug-related policies set out in the draft version released in January (1"The Pink Sheet," Jan. 28, 2008, p. 27). To increase transparency on prior authorization requirements, the final call letter requires that sponsors compile such criteria in a standardized format and post it on plan Web sites. CMS will no longer allow plans to impose prior authorization requirements for Roche's HIV therapy Fuzeon (enfuvirtide), nor will the agency permit gap coverage to be limited to mail order drug purchases. In one change, CMS backs off the proposed requirement for electronic prescription reporting in 2009 and announces it will not make such reporting mandatory until 2010

You may also be interested in...

CMS Seeks Part D Prior Authorization Criteria Transparency In 2009

CMS is aiming to make Medicare Part D formulary prior authorization practices more clear and consistent by proposing new requirements for drug plans in its draft "call letter" to prospective plan sponsors for the 2009 benefit year

Watch Out Pfizer, Moderna - India’s First mRNA Vaccine Is Here

With India’s first and the world’s third mRNA vaccine, Gennova plans to provide access to its COVID-19 vaccine to those deprived of doses from Pfizer and Moderna. HDT Bio Corp’s suit in the US is not seen impacting marketing plans in India, COO tells Scrip

CEO Kevin Ali Marks Organon’s Progress In First Post-Spin Year

A year after Organon spun out of Merck, the company has delivered on its financial guidance, generated double-digit biosimilars sales growth and executed six deals to grow in women’s health.

Latest News



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts